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Akt regulates critical cellular processes including cell survival and proliferation, glucose metabolism, cell migration,
cancer progression and metastasis through phosphorylation of a variety of downstream targets. The Akt pathway is
one of the most prevalently hyperactivated signaling pathways in human cancer, thus, research deciphering
molecular mechanisms which underlie the aberrant Akt activation has received enormous attention. The PI3K-dependent
Akt serine/threonine phosphorylation by PDK1 and mTORC2 has long been thought to be the primary mechanism
accounting for Akt activation. However, this regulation alone does not sufficiently explain how Akt hyperactivation
can occur in tumors with normal levels of PI3K/PTEN activity. Mounting evidence demonstrates that aberrant Akt
activation can be attributed to other posttranslational modifications, which include tyrosine phosphorylation,
O-GlcNAcylation, as well as lysine modifications: ubiquitination, SUMOylation and acetylation. Among them, K63-linked
ubiquitination has been shown to be a critical step for Akt signal activation by facilitating its membrane recruitment.
Deficiency of E3 ligases responsible for growth factor-induced Akt activation leads to tumor suppression. Therefore, a
comprehensive understanding of posttranslational modifications in Akt regulation will offer novel strategies for cancer
therapy.
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Akt, also known as protein kinase B (PKB), was originally
identified as the cellular homologue of the viral oncogene,
v-akt [1,2]: a serine/threonine kinase similar to protein
kinases A and C [3,4]. Akt serves as a central hub that
transduces various extracellular cues to regulate a wide
range of biological processes through phosphorylation
of distinct protein substrates. For instance, Akt phos-
phorylates and inhibits FoxOs, GSK3β, TCS2 and Bad
[5]. FoxOs, when phosphorylated by Akt are seques-
tered in the cytoplasm where they fail to induce tran-
scription of genes associated with apoptosis and cell
cycle arrest [6]. Akt phosphorylation of GSK3β, a protein
kinase known to downregulate protein substrates for cell
survival and proliferation, causes cells to reacquire survival
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unless otherwise stated.complex 1 (mTORC1), a protein complex essential for pro-
tein translation and cell growth. The phosphorylation of
TSC2 by Akt allows the reactivation of mTORC1 [8,9]. Akt
phosphorylation of Bad, a pro-apoptotic protein that
controls mitochondrial outer membrane permeability,
decreases cytochrome c release to protect cells from apop-
tosis [10]. Akt-regulated phosphorylation can also provoke
the activation of substrates like IKKα and Skp2 [11-13].
Akt phosphorylates and activates IKKα, leading to the
induction of immune response through upregulation of
NF-κB. Skp2 is an F-box protein constituting the Skp2
SCF E3 ubiquitin ligase complex and is essential for cell
cycle progression, migration and metastasis [13-16]. Akt-
mediated phosphorylation of Skp2 stabilizes and activates
Skp2 and facilitates its cytosolic translocation, thereby
promoting cell migration and cancer metastasis [12,13,17].
Change in Akt expression level or activity is a causative
factor for the onset or progression of a variety of human
cancers [18-20]. Therefore, there is great enthusiasm in
the scientific community for a better understanding of
the regulatory mechanisms that underlie abnormaltd. This is an Open Access article distributed under the terms of the Creative
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three isoforms in mammals [21,22]. Akt1 is ubiqui-
tously expressed in various tissues at high levels. Akt2
is highly expressed in the muscle, liver and adipose tis-
sues while modestly expressed in other tissues. Akt3 is
predominantly expressed in brain and testis. These
three isoforms sharing high sequence and structural
homology consists of an amino-terminal pleckstrin
homology (pH) domain and a carboxyl-terminal regu-
latory domain. Since these Akt isoforms are similarly
activated by PI3K and PDK1 and share some common
downstream effectors, it is postulated that the Akt iso-
forms may be functionally redundant. However, accumu-
lating evidence suggests differential substrate specificity
and biological functions among Akt isoforms (reviewed by
B. Dummle and B.A. Hemmings) [23]. These observations
therefore redirect scientists’ attention to the roles of each
Akt isoform in physiological and pathological conditions.
A plethora of downstream players for each Akt iso-
form have been discovered and characterized [5,23] and
the involvement of many substrates in specific biological
functions and diseases has been comprehensively illus-
trated (reviewed by B.D. Manning and L.C. Cantley)
[5,23]. In this review, we will summarize recent advances
in the posttranslational regulation of Akt, discuss the
possible roles of Akt regulators affecting Akt posttransla-
tional modifications in cancer development and potentially
provide new therapeutic strategies for cancer targeting.
Phosphorylation and activation of Akt
Extensive studies have established that growth factors,
hormones and cytokines stimulate Akt activation through
serial phosphorylation events [24,25]. The binding of lig-
and to its cognate receptor tyrosine kinase (RTK) causes
PI3K activation that converts phospholipid PIP2 to
phospholipid PIP3. PIP3 then interacts with and recruits
both Akt and phosphoinositide-dependent kinase 1
(PDK1) to the plasma membrane where PDK1 can phos-
phorylate Akt at threonine (Thr308) in the activation loop,
consequently keeping Akt in its active conformation [26].
While this phosphorylation is sufficient to activate some
Akt downstream substrates, additional phosphorylation in
the C-terminal domain at serine 473 (Ser473) by mTORC2
accounts for the full activation of Akt [27]. Other than
mTORC2, kinases including DNA-dependent protein
kinase (DNA-PK), integrin-linked kinase (ILK), and
mitogen-activated protein kinase-activated protein kinase-2
(MAPKAPK2) have been implicated in the modulation
of Akt phosphorylation at Ser473 in various contexts
[28-31]. Most recently, Wei’s group uncovered a novel
phosphorylation event that critically regulates Akt acti-
vation under diverse physiological conditions. They
found that Akt S477/T479 phosphorylation can be trig-
gered by cyclin-dependent kinase 2 (cdk2)/cyclinA,mTORC2, and DNA-PK under cell cycle progression,
growth factor stimulation and DNA damage response
[32,33]. While Akt S477/T479 phosphorylation is es-
sential for Akt activation and Akt-regulated biological
functions, it remains obscure how this phosphorylation
orchestrates Akt activation [32]. It will be interesting to
determine whether Akt S477/T479 phosphorylation
regulates Akt activation by affecting its membrane re-
cruitment under such physiological cues.
Conversely, phosphatase and tensin homolog (PTEN)
is a phosphatase that dephosphorylates PIP3 to prevent
Akt membrane recruitment and phosphorylation [34].
Multiple lines of genetic evidence demonstrate that
PTEN loss results in aberrant hyperactivation of Akt that
renders PTEN-deficient mice to predispose to neoplasia
and tumors [35]. In addition to PTEN, two phosphatases,
protein phosphatase 2A (PP2A) and PH domain and leu-
cine rich repeat protein phosphatase (PHLPP), were found
to dephosphorylate Akt at Thr308 and Ser473, respect-
ively, thereby antagonizing Akt activation [36-38].
Besides PI3K and the upstream kinases and phospha-
tases of Akt, several proteins indirectly involved in cycles
of serine/threonine phosphorylation and dephosphoryla-
tion of Akt have been identified. For instance, promyelo-
cytic leukemia protein (PML) represses Akt activation as
it is essential for PP2A-mediated Akt dephosphorylation
at Thr308 [39]. Consequently, genetic ablation of PML
causes prostate tumors in mice accompanied by eleva-
tion of Akt phosphorylation and activation [39]. In the
context of dopamine stimulation, Caron’s group showed
that β-arrestin-2 facilitates the interaction of PP2A with
Akt, leading to dephosphorylation and inhibition of Akt
[40,41]. Further genetic evidence showed β-arrestin-2
knockout mice exhibit defects in dopamine-mediated
neurotransmission and Akt inactivation in the central
nervous system [24,25]. Similarly, FK506 binding protein
51 (FKBP51) works to bridge PHLPP and Akt leading to
Ser473 dephosphorylation and subsequent inactivation
of Akt [42].
Multiple studies present evidence that Akt undergoes
tyrosine phosphorylation in response to diverse growth
factors, such as EGF, Heregulin and insulin. Upon EGF
stimulation, Akt is phosphorylated at Tyr315 and Tyr326
by Src or protein tyrosine kinase 6 (PTK6), a Src-related
tyrosine kinase [43,44]. Both Qiu’s and Tyner’s groups re-
ported that phosphorylation of Akt at Tyr315 and Tyr326
is required for its kinase activation, as substitution of these
residues with phenylalanine abolishes its kinase activity.
While Qiu’s study suggests that PI3K activation is essential
for Akt tyrosine phosphorylation, Tyner’s work does not
support this notion. This discrepancy may be due to the
different concentrations of EGF and the different cell types
used in their studies. Nevertheless, Luan and colleagues
revealed that enhanced Akt tyrosine phosphorylation by
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negative role in Akt activation upon dopamine stimula-
tion, β-arrestin-2 facilitates Akt activation by recruiting
Akt to active Src and the insulin receptor complex for its
tyrosine phosphorylation upon exposure to insulin [45]. In
line with this observation, loss of β-arrestin-2 results in
defective Akt activation and attenuates insulin signaling,
thereby leading to insulin resistance and type II diabetes
in mouse models [45]. Altogether, β-arrestin-2 functions
as a contextual Akt regulator that can instigate opposing
effects on Akt. Thus, caution should be taken when
considering β-arrestin-2 as a target for therapeutic
intervention.
Akt can also be phosphorylated at Tyr176 by Ack1 upon
activation of RTK by growth factors [46]. Mahajan and
colleagues have shown that Akt Tyr176-phosphorylation
is sufficient to drive its membrane localization and subse-
quent PDK1- and mTORC2-mediated Akt phosphoryl-
ation and activation. Interestingly, the Ack1-mediated Akt
tyrosine phosphorylation remains unchanged in the pres-
ence of PI3 kinase inhibitor, LY294002. This finding not
only lends a support but also offers a molecular mechan-
ism for the previous notion that Akt activation can occur
in a PI3K-independent manner [47-49]. Experiments using
transgenic mice expressing constitutively active Ack1
in prostate tissues show an elevation of Tyr176-
phosphorylation and activation of Akt in vivo. Further,
these mice develop prostatic intraepithelial neoplasia
(PIN) similar to those driven by Akt hyperactivation.
However, it is unclear whether Ack1 is required for
prostate cancer development upon conditional PTEN
inactivation in prostates.
Lysine modifications (ubiquitination, SUMOylation and
acetylation) of Akt
Phosphorylation and dephosphorylation are regarded as
the primary mechanism driving Akt signal activation.
Recent advances reveal that other posttranslational mod-
ifications including ubiquitination and SUMOylation are
also essential and equally important as phosphorylation
for Akt signaling activation.
Ubiquitination, just like phosphorylation, is a dynamic
modification engaged in diverse cellular processes in-
cluding cell growth and proliferation, apoptosis, DNA
damage response, inflammation, cancer and neurodegen-
erative diseases [50-55]. It is an enzyme-catalyzed cascade
that not only marks protein substrates for 26S proteasome-
dependent degradation by covalently conjugating them with
multiple ubiquitin monomers via lysine (K)48-linkage, but
also alters protein localization, trafficking and/or activation
via K63-linked polyubiquitin chains [56,57]. The vital role
of ubiquitination in regulating Akt degradation and inacti-
vation has been recently defined. For instance, CHIP,
BRCA1, TTC3, and MULAN ubiquitin ligases have beenshown to promote K48-linked ubiquitination and degrad-
ation of Akt to terminate its activation [58-61].
In 2009, our group presented the first evidence that
Akt can undergo K63-linked ubiquitination at K8 and
K14 residues within its PH domain in response to IGF-1
and cytokine IL-1 stimulation. In contrast to K48-linked
ubiquitination and degradation, this K63-linked ubiquiti-
nation does not trigger Akt degradation. Instead, it is re-
quired for Akt membrane recruitment, serine/threonine
phosphorylation and activation [62]. TRAF6 was the first
example of an E3 ligase that orchestrates Akt signaling
activation by promoting its K63-linked ubiquitination
[62]. In line with this study, a later report showed that
Nedd4 is another E3 ligase which regulates K63-linked
ubiquitination of Akt in IGF-1 signaling [63]. In 2012
and 2014, we and other group further showed that EGF-
mediated Akt activation also requires K63-linked ubiqui-
tination of Akt, which is induced by Skp2 or TRAF4
[64,65]. Experiments using either xenograft or genetic
mouse models illustrated that deficiency in Skp2, TRAF6
or TRAF4 results in suppression of cancer development
in vivo, pointing to the critical role of distinct E3 ubiqui-
tin ligases in Akt-mediated biological functions and cancer
progression. Notably, ablation of Skp2 mitigates the eleva-
tion of Akt phosphorylation and activation in tumors tis-
sues driven by overexpressed Her2/Neu oncoprotein [64].
Altogether, these studies suggest that various extracellular
signals utilize distinct E3 ubiquitin ligases to orchestrate
Akt signaling activation. Future studies are needed to de-
fine the mechanism by which distinct E3 ubiquitin ligases
are selectively utilized for Akt activation by diverse extra-
cellular signals. Since Akt signaling pathways are also acti-
vated by other growth factors and cytokines, such as FGF,
PDGF and insulin, it will be interesting to determine
whether K63-linked ubiquitination of Akt is a general
mechanism for Akt signaling activation beyond IGF-1,
EGF and IL-1. If it is the case, what E3 ubiquitin ligases
are also engaged in Akt activation other than Nedd4,
Skp2, TRAF4 and TRAF6? Even under stimulation by the
same ligand, Akt activity can be modulated by more than
one E3 ligase. What is the crosstalk between these E3
ligases in Akt activation? It would be interesting to
know how they work together: redundantly, comple-
mentarily or distinctly?
The ubiquitination can be reversed by deubiquitinating
enzymes (DUBs). Recently, two independent studies re-
ported that the tumor suppressor CYLD can function as
a DUB for Akt. CYLD can terminate Akt activity by re-
moving Akt K63-linked ubiquitin chains induced by dif-
ferent inducers, including growth factors and lung injury
stimuli [66,67]. Thus, CYLD serves as a negative regula-
tor for Akt-mediated tumorigenesis and lung fibrosis.
These reports suggest that the K63-linked ubiquitination
is a universal mechanism for Akt regulation at least
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score the crucial role of cycles of ubiquitination and
deubiquitination in Akt plasma membrane localization
and activation. Several questions remain to be answered.
For examples, what mechanism causes CYLD to switch
off Akt from the ubiquitinated (active) to deubiquiti-
nated form (inactive)? Is CYLD the sole actor or are
there more DUBs responsible for Akt deubiquitination
and regulation?
Besides ubiquitination, multiple frequent posttransla-
tional modifications occur at lysine residues, such as
SUMOylation and acetylation. Li and colleagues system-
atically screened 34 lysine residues on Akt to determine
which sites are engaged in Akt activation by analyzing
phosphorylation of Akt and its downstream target,
GSK3β. This study supports the previous finding that
the K14 residue, modified by K63-linked ubiquitination,
is essential for Akt phosphorylation and activation [68].
Consistent with previous observations, mutation of
K179, the ATP-binding site, impairs the activation of
GSK3β without impact on the serine/threonine phos-
phorylation of Akt [68]. Other than residues K14 and
K179, replacement of lysine with arginine at K168, 183,
or K276 reduces the phosphorylation of GSK3β by Akt
but has negligible impact on the phosphorylation state
of Akt. Among these sites, K276 was identified as a
major receptor site for SUMOylation, which is provoked
by the SUMO E3 ligase PIAS1 and reversed by the
SUMO-specific protease SENP1 [68]. Another biochem-
ical analysis revealed that K301, like K276, is also a preva-
lent SUMO attachment site on Akt. Moreover, double
mutation on K276 and K301 residues of Akt was found to
attenuate Akt-regulated cellular processes independently
of Akt phosphorylation [69]. Even though SUMOylation
of Akt is critical for Akt activation, the mechanism ac-
counting for its activation remains to be determined. It’s
worth mentioning that SUMOylation can occur on all
three Akt isoforms while K63-linked ubiquitination can be
detected in Akt1 and Akt2 but not Akt3. These observa-
tions imply that K63-linked ubiquitination and SUMOyla-
tion may activate Akt through different mechanisms—at
least in Akt3.
Acetylation is another lysine modification that can
negatively regulate Akt activity [70]. It has been demon-
strated that the level of Akt acetylation induced by IGF-1
or insulin inversely correlates with Akt phosphorylation
and signaling [70]. p300 and p300/CBP-associated factor
(PCAF) are the aceyltransferases that induce Akt acetyl-
ation and inactivation, whereas sirtuin 1 (SIRT1) deacety-
lates Akt to promote Akt binding to PIP3 and consequent
Akt activation [70]. Consistent with these observations,
SIRT1 deficiency compromises Akt participation in cell
survival, proliferation and tumorigenesis. Mass spectrom-
etry analysis revealed that Akt is acetylated at K14 andK20 within its PH domain. While the Akt acetylation-
defective mutant, K20R, exhibits increased PIP3 binding
and Akt membrane localization, the K20Q mutant that
mimics constitutive Akt acetylation increases Akt activity,
recapitulating the effect of SIRT1 deficiency. However, the
other acetylation defective Akt mutant (K14R) does not
enhance Akt phosphorylation as expected and activation
due to the fact that it also affects K63-linked Akt ubiquiti-
nation. Thus, it is likely that the loss of K63-linked ubiqui-
tination offsets enhanced Akt membrane translocation
and activation by the loss of Akt acetylation. While several
lysine modifications on Akt have been uncovered, more
studies will be required to decipher the potential crosstalk
among diverse lysine modifications on Akt.Glycosylation of Akt
O-GlcNAcylation is a reversible process, which modifies
serine/threonine residues of proteins with a specific glycan:
β-N-acetylglucosamine. Some studies have demonstrated
that elevated protein O-GlcNAcylation by overexpression
of O-GlcNAc transferase or inhibitors of O-GlcNAcases re-
sults in decreased Thr 308 phosphorylation of Akt and thus
insulin resistance [71,72]. However, whether Akt can be the
target for O-GlcNAcylation was not characterized in these
studies. Subsequent study from Soesanto and colleagues
reports that Akt itself can undergo O-GlcNAcylation
[73]. Geng’s and Gong’s groups later demonstrated that
O-GlcNAcylation of Akt inhibits its Thr 308 phosphor-
ylation in various cell types [74,75]. Geng’s group fur-
ther mapped the O-GlcNAcylation sites of Akt and
illustrated that O-GlcNAcylation occurs at Thr305 and
Thr312. Intriguingly, O-GlcNAcylation of Akt attenu-
ates Akt phosphorylation at Thr308 and Akt-mediated
biological functions by blocking the binding of Akt to
PDK1. Although O-GlcNAcylation of Akt on Ser126 and
Ser129 was also reported, the progress toward under-
standing the functional significance of O-GlcNAcylation
on these two sites was hindered by the fact that Ser126
and Ser129 are also Akt phosphorylation sites. Experi-
ments comparing the effects of O-GlcNAcylation versus
phosphorylation of Akt on Ser126 and Ser129 are ne-
cessary to determine the predominant and functional
relevance of these modifications on these sites. Further-
more, the interplay between of O-GlcNAcylation and
phosphorylation on Ser126 and Ser129 in Akt regula-
tion remains to be elucidated.Akt signaling in human cancer
Although mutations in Akt are rarely found, Akt signaling
is one of the most frequently hyperactivated pathways in
many human cancers. Several mechanisms accounting for
this aberrant activation have been proposed. These in-
clude mutation or amplification of PIK3C gene that
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RTKs. Thus, development of inhibitors targeting PI3K-
Akt pathway has received enormous attention in the past
decade [76,77]. The antitumor activities of specific PI3K
or dual PI3K/mTOR inhibitors have been reported in sev-
eral preclinical models [78-81]. In theory, the dual PI3K/
mTOR inhibitors should lead to the maximal inhibition of
PI3K-Akt pathway as they can simultaneously target PI3K,
mTORC1 and mTORC2. The potential therapeutic bene-
fits in patients and adverse effects that may come with
these inhibitors are currently being evaluated in a number
of clinical trials (the progress of the specific PI3K or dual
PI3K/mTOR inhibitors in clinical trials is comprehensively
reviewed by C. Porta) [82]. Among these, NVP-BEZ235,
an ATP-competitive dual inhibitor for PI3K and mTOR, is
currently in phase I/II clinical trials for advanced solid
tumors. Although the clinical benefits of NVP-BEZ235
are being assessed, multiple resistance mechanisms are
already known in prostate, breast and renal cell carcin-
omas (RCC) cells, among others. Inhibition of the
PI3K/Akt pathway by NVP-BEZ235 activates androgen
receptor signaling by relieving feedback inhibition of Her2
kinases [83,84], thus maintaining tumor cell growth in
PTEN-deficient murine prostate cancer models. Similarly,
use of NVP-BEZ235 in breast and RCC cells induces
feedback regulations to sustain cell survival via ERK-
and the FoxO/mTORC2-dependent pathways, respect-
ively [85,86]. These findings highlight that combination
therapies of NVP-BEZ235 with inhibitors that target
the respective resistance pathways prevalent in each
cellular context should be considered in order to
maximize the therapeutic efficacy in the clinic setting.Figure 1 Schematic representation of post-translational modifications
Akt are shown together with their regulating proteins. PH (Pleckstrin homolog
indicate amino acid position.Further studies are needed to unravel comprehensive
resistance mechanisms that cancer cells may evolve to
survive in the presence of NVP-BEZ235 or other PI3K
inhibitors. This information will provide rationale for
combination therapy in cancer patients.
Membrane translocation is known to be prerequisite
for Akt phosphorylation and signal activation. Perifosine
is a PH domain inhibitor that targets Akt activity via
perturbing membrane translocation of Akt and has been
proven as the most clinically advanced Akt inhibitor
[87]. However, perifosine along with other pH domain,
lipid-based Akt inhibitors such as PX-316 [88], inhibit
not only Akt but also other pH domain containing pro-
teins. Hence, specificity and the potential for severe side
effects, like hemolysis, are common issues needed to be
resolved for the class of PH domain Akt inhibitors. A
growing body of evidence has shown that cycles of K63-
linked ubiquitination of Akt provide dynamic and pre-
cise control of Akt activity by regulating its membrane
localization [62-67]. The discoveries that cancer-associated
Akt E17K mutant exhibits higher basal level of K63-linked
ubiquitination than wild-type Akt provide an underlying
mechanism through which the Akt E17K mutant acquires
increased activity and oncogenic potentials in cancer
[47,62,63]. This observation highlights the physiological
relevance of K63-linked ubiquitination in Akt regulation
and further suggests that E3 ligases responsible for growth
factor induced K63-linked ubiquitination of Akt can serve
as a new class of therapeutic targets in cancer treatment
[89]. Indeed, deficiency of Akt E3 ligases including Skp2,
TRAF6 and TRAF4 suppresses tumor growth in vivo. In
agreement with these genetic findings, the specific Skp2of Akt. Domain structure and post-translational modification sites of
y domain), KD (Kinase domain), and RD (Regulatory domain). Numbers
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regulates Akt phosphorylation and represses tumor growth
in pre-existing cancer xenografts [90,91]. These studies
open an avenue to treat human cancers by targeting E3 li-
gases for K63-linked Akt ubiquitination.Conclusion and perspectives
Research on Akt regulation by serine/threonine phos-
phorylation has taken center stage for years, and Akt and
its upstream regulators, like PI3K, have been targeted for
cancer therapies. The discovery of other posttranslational
modifications such as ubiquitination, SUMOylation,
acetylation and glycosylation adds further complexity to
the diverse regulatory networks controlling Akt signaling
activation (Figure 1). Even though aberrant deregulation
of PI3K and PTEN activity is a prevalent cause for Akt
hyperactivation in human cancers, mechanisms other
than PI3K/PTEN deregulation have emerged [47-49].
Recent advances reveal that K63-linked ubiquitination,
SUMOyation and perhaps tyrosine phosphorylation can
contribute to Akt signaling activation in a PI3K-
independent fashion, indicating that these modifica-
tions may be alternative mechanisms accounting for
aberrant Akt hyperactivation in human cancers. Thus,
the identification of proteins responsible for these
modifications will provide important insights for can-
cer treatment.
Accumulating evidence illustrates that different Akt
isoforms are responsible for their diverse biological func-
tions [92-94]. In particular, Akt1 and Akt2 seem to have
opposing roles in cancer metastasis despite the similarity
of their activation mode by PI3K stimulation [95-98].
This may explains the poor efficacy of PI3K inhibitors in
advanced human cancers. It also suggests that deeper
understanding of the roles of PTMs on the activation of
different Akt isoforms over the course of cancer progres-
sion and metastasis could be beneficial for therapeutic
outcomes. Limited evidence has been presented that
K63-linked ubiquitination and SUMOylation can effi-
ciently modify both Akt1 and Akt2 [62,64,69], suggesting
that neither modification is the major contributor for
the diverse functions of Akt1 and Akt2 in metastasis.
Further effort is required to define what PTMs may be
associated with the activation of distinct Akt isoforms.
This knowledge will offer an opportunity to develop spe-
cific inhibitors against each Akt isoform.
Despite the enormous progress made for the role of
PTMs in Akt regulation, several outstanding questions re-
main to be addressed. While both K63-linked ubiquitina-
tion and SUMOylation have been shown to drive Akt
localization to either membrane and/or nucleus, the under-
lying mechanism dictating Akt trafficking remains un-
known. Do K63-linked ubiquitination and SUMOylationemploy the same regulatory machinery for Akt trafficking
even though modifications occur at different sites? What
determines the biological consequences when distinct mod-
ifications occur on the same residues of Akt? For instance,
both K63-linked ubiquitination and acetylation can occur
at K14 upon IGF1 stimulation. How do they work differ-
ently to coordinately regulate Akt activation in response to
IGF-1? Another example is how phosphorylation and
O-GlcNAcylation of Akt can occur on the same sites of
Akt (Ser126 and Ser129). Are these two modifications
mutually exclusive or interdependent? Comprehensive
understanding of physiologically importance of cross-
talk between PTMs in Akt regulation may provide bet-
ter strategies for the fight against cancer.
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